Rhythm Pharmaceuticals, Inc. RYTM Single reportable segment — Preclinical, clinical and development expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept rytm:PreclinicalClinicalAndDevelopmentExpense.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s single reportable segment — preclinical, clinical and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s single reportable segment — preclinical, clinical and development expense?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported single reportable segment — preclinical, clinical and development expense of $18.51M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s single reportable segment — preclinical, clinical and development expense changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s single reportable segment — preclinical, clinical and development expense decreased by 7.3% year-over-year, from $19.96M to $18.51M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s single reportable segment — preclinical, clinical and development expense?
- Over 3 years (2022 to 2025), Rhythm Pharmaceuticals, Inc.'s single reportable segment — preclinical, clinical and development expense has grown at a 9.8% compound annual growth rate (CAGR), from $66.01M to $87.32M.
- What does single reportable segment — preclinical, clinical and development expense mean?
- This metric encompasses the costs associated with the research, discovery, and clinical testing of new drug candidates. It includes expenses for laboratory studies, clinical trials, and regulatory filings necessary to bring therapies to market. This is a critical indicator of the company's commitment to innovation and its long-term pipeline potential.